Luminescence-based methods and probes for measuring cytochrome P450 activity
View Patent ↗The present invention provides methods, compositions, substrates, and kits useful for analyzing the metabolic activity in cells, tissue, and animals and for screening test compounds for their effect on cytochrome P450 activity. In particular, a one-step and two-step methods using luminogenic molecules, e.g. luciferin or coelenterazines, that are cytochrome P450 substrates and that are also bioluminescent enzyme, e.g., luciferase, pro-substrates are provided. Upon addition of the luciferin derivative or other luminogenic molecule into a P450 reaction, the P450 enzyme metabolizes the molecule into a bioluminescent enzyme substrate, e.g., luciferin and/or luciferin derivative metabolite, in a P450 reaction. The resulting metabolite(s) serves as a substrate of the bioluminescent enzyme, e.g., luciferase, in a second light-generating reaction. Luminescent cytochrome P450 assays with low background signals and high sensitivity are disclosed and isoform selectivity is demonstrated. The present invention also provides an improved method for performing luciferase reactions which employs added pyrophosphatase to remove inorganic pyrophosphate, a luciferase inhibitor which may be present in the reaction mixture as a contaminant or may be generated during the reaction. The present method further provides a method for stabilizing and prolonging the luminescent signal in a luciferase-based assay using luciferase stabilizing agents such as reversible luciferase inhibitors.
1. A compound selected from the group consisting of
4,5-dihydro-2-(6-(2-chloroethoxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 2-chloroethyl ether);
4,5-dihydro-2-(6-(benzyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ benzyl ether);
4,5-dihydro-2-(6-(4-picolinyloxy)-benzothiazolyl-4-thiazolecarboxylic acid (luciferin 6′ 4-picolinyl ether);
4,5-dihydro-2-(6-(4-trifluoromethylbenzyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 4-trifluoromethylbenzyl ether);
4,5-dihydro-2-(6-(phenylethoxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ phenylethyl ether);
4,5-dihydro-2-(6-(geranyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ geranyl ether);
4,5-dihydro-2-(6-(prenyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ prenyl ether);
4,5-dihydro-2-(6-(2-picolinyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 2-picolinyl ether); and
4,5-dihydro-2-(6-(3-picolinyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 3-picolinyl ether).
2. The compound according to claim 1 selected from the group consisting of
4,5-dihydro-2-(6-(benzyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ benzyl ether);
4,5-dihydro-2-(6-(phenylethoxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ phenylethyl ether);
4,5-dihydro-2-(6-(geranyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ geranyl ether); and
4,5-dihydro-2-(6-(prenyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ prenyl ether).
3. The compound according to claim 1 selected from the group consisting of
4,5-dihydro-2-(6-(2-chloroethoxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 2-chioroethyl ether);
4,5-dihydro-2-(6-(4-picolinyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 4-picolinyl ether);
4,5-dihydro-2-(6-(4-trifluoromethylbenzyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 4-trifluoromethylbenzyl ether);
4,5-dihydro-2-(6-(2-picolinyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 2-picolinyl ether); and
4,5-dihydro-2-(6-(3-picolinyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 3-picolinyl ether).
4. A compound having the formula:
wherein
R 1 represents hydrogen, hydroxy, C 1-20 alkoxy or C 1-20 alkenyloxy, wherein the alkoxy are substituted with halogen, hydroxy, amino, cyano, azido, heteroaryl or aryl substituted with haloalkyl; or
R 1 represents C 3-20 alkynyloxy; or cycloalkoxy, each optionally substituted with halogen, hydroxy, amino, cyano, azido, heteroaryl or aryl substituted with haloalkyl;
R 2 and R 3 independently represent C or N;
R 4 and R 5 independently represent S, O, NR 8 wherein R 8 represents hydrogen or C 1-20 alkyl, or CR 9 R 10 wherein R 9 and R 10 independently represent H, C 1-20 alkyl or fluorine;
R 6 represents CH 2 OH; COR 11 wherein R 11 represents hydrogen, hydroxy, C 2-20 alkenyl, or —OM + wherein M + is an alkali metal or a pharmaceutically acceptable salt; and
R 7 represents hydrogen, C 1-6 alkyl, C 2-20 alkenyl, halogen or C 1-6 alkoxy; provided that
when R 1 is hydroxy, R 7 is not hydrogen, R 11 is not hydroxy, R 2 and R 3 are not both carbon, and R 4 and R 5 are not both S ((4S)-4,5-dihydro-2-(6-hydroxy-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin));
when R 1 is hydrogen, R 7 is not hydrogen, R 11 is not hydroxy, R 2 and R 3 are not both carbon, and R 4 and R 5 are not both S ((4S)-4,5-dihydro-2-(benzothiazolyl)-4-thiazolecarboxylic acid ((dehydroluciferin)); and
when R 1 is hydroxy, R 7 is not hydrogen, R 6 is not CH 2 OH, R 2 and R 3 are not both carbon, and R 4 and R 5 are not both S (2-(4-(hydroxymethyl)-4,5-dihydrothiazol-2-yl)benzo[d]thiazol-6-ol(luciferol)).
5. A composition comprising a compound of claim 4 and a buffer.
6. The composition of claim 5 , further comprising a pyrophosphatase.
7. The composition according to claim 6 wherein the pyrophosphatase is an inorganic pyrophosphatase.
8. The composition according to claim 5 wherein the compound is
4,5-dihydro-2-(6-(2-chloroethoxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 2-chioroethyl ether);
4,5-dihydro-2-(6-(4-picolinyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 4-picolinyl ether);
4,5-dihydro-2-(6-(4-trifluoromethylbenzyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 4-trifluoromethylbenzyl ether);
4,5-dihydro-2-(6-(2-picolinyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 2-picolinyl ether); or
4,5-dihydro-2-(6-(3-picolinyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ 3-picolinyl ether).
9. The composition of claim 8 , further comprising a pyrophosphatase.
10. The composition according to claim 9 wherein the pyrophosphatase is an inorganic pyrophosphatase.
11. The composition according to claim 5 wherein the compound is
4,5-dihydro-2-(6-(benzyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ benzyl ether);
4,5-dihydro-2-(6-(phenylethoxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ phenylethyl ether);
4,5-dihydro-2-(6-(geranyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ geranyl ether); or
4,5-dihydro-2-(6-(prenyloxy)-benzothiazolyl)-4-thiazolecarboxylic acid (luciferin 6′ prenyl ether).
12. The composition of claim 11 , further comprising a pyrophosphatase.
13. The composition according to claim 12 wherein the pyrophosphatase is an inorganic pyrophosphatase.
14. The compound according to claim 4 that has the structure
or a salt thereof.
15. The compound according to claim 4 that has the structure
or a salt thereof.
16. The compound according to claim 4 that has the structure
or a salt thereof.
17. The compound according to claim 4 that has the structure
or a salt thereof.
18. The compound according to claim 4 that has the structure
or a salt thereof.
19. The compound according to claim 4 that has the structure
or a salt thereof.
20. The compound according to claim 4 that has the structure
or a salt thereof.
21. The compound according to claim 4 that has the structure
or a salt thereof.
22. The compound according to claim 4 that has the structure
or a salt thereof.